Richter Yields to Government Price Restriction Demand

The Hungarian pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that “understanding and supporting the Hungarian government's efforts to reduce the burden on patients, voluntarily restricts the price of its non-prescription product Panangin®, a magnesium and potassium dietary supplement and complementary treatment for chronic heart disease and cardiac arrhythmias, from June 16, 2025.”

Under the price restriction, the producer price of the product will be reduced to the level that was in place on December 31, 2024. However, Richter also points out that the final consumer price does not solely depend on the producer price, but it is also influenced by the wholesale and retail price margins, over which the company has no control. The annual impact of the price restriction is estimated to be around HUF 100 million.

Although domestic sales account for only 7% of total sales, the Hungarian market is of particular importance to Richter, where it makes a significant contribution to the stability and security of patient care as a key player in the primary care market, with a market share of around 6.5% by value.